OPAXVIZ Trademark

Trademark Overview

On Friday, December 17, 2021, a trademark application was filed for OPAXVIZ with the United States Patent and Trademark Office. The USPTO has given the OPAXVIZ trademark a serial number of 97178334. The federal status of this trademark filing is FIFTH EXTENSION - GRANTED as of Thursday, October 17, 2024. This trademark is owned by Biogen MA Inc.. The OPAXVIZ trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of eye diseases, disorders, and conditions; ophthalmologic pharmaceutical preparations
opaxviz

General Information

Serial Number97178334
Word MarkOPAXVIZ
Filing DateFriday, December 17, 2021
Status734 - FIFTH EXTENSION - GRANTED
Status DateThursday, October 17, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 1, 2022

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of eye diseases, disorders, and conditions; ophthalmologic pharmaceutical preparations

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, December 22, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBIOGEN INTERNATIONAL GMBH
Party Type21 - New Owner After Publication
Legal Entity Type27 - NOT AVAILABLE
AddressBAAR 6340
CH
Party NameBiogen MA Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142
Party NameBiogen MA Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142

Trademark Events

Event DateEvent Description
Wednesday, December 22, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, December 21, 2021NEW APPLICATION ENTERED
Wednesday, January 5, 2022ASSIGNED TO EXAMINER
Monday, January 10, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, January 14, 2022ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Thursday, January 20, 2022ELECTRONIC RECORD REVIEW COMPLETE
Wednesday, February 9, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 1, 2022PUBLISHED FOR OPPOSITION
Tuesday, March 1, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 26, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, October 6, 2022SOU TEAS EXTENSION RECEIVED
Thursday, October 6, 2022SOU EXTENSION 1 FILED
Thursday, October 6, 2022SOU EXTENSION 1 GRANTED
Saturday, October 8, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 24, 2023SOU TEAS EXTENSION RECEIVED
Monday, April 24, 2023SOU EXTENSION 2 FILED
Monday, April 24, 2023SOU EXTENSION 2 GRANTED
Wednesday, April 26, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 19, 2023SOU TEAS EXTENSION RECEIVED
Thursday, October 19, 2023SOU EXTENSION 3 FILED
Thursday, October 19, 2023SOU EXTENSION 3 GRANTED
Saturday, October 21, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 29, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, November 29, 2023SOU EXTENSION 4 FILED
Wednesday, November 29, 2023SOU EXTENSION 4 GRANTED
Thursday, November 30, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 17, 2024SOU TEAS EXTENSION RECEIVED
Thursday, October 17, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 17, 2024SOU EXTENSION 5 FILED
Thursday, October 17, 2024SOU EXTENSION 5 GRANTED
Thursday, May 30, 2024AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP

Related Keywords

opaxviz pharmaceutical preparations conditions ophthalmologic diseases treatment disorders